Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Topical Corticosteroid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Topical Corticosteroid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Topical Corticosteroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
effects of oral corticosteroids may also occur with topicalcorticosteroids, especially in children, including: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Growth suppression. Visual disturbance — if a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation of possible causes that may include cataract, glaucoma, or rare diseases (...) review Choosing topicalcorticosteroids [ ], and the summary of product characteristics for Betnovate cream [ ]. Systemic adverse effects An Australasian College of Dermatology consensus statement on the adverse effects of topicalcorticosteroids in paediatric eczema [ ] states that physiological hypothalamic-pituitary-adrenal (HPA) axis suppression can occur with very widespread and prolonged, or occlusive use of potent/superpotent topicalcorticosteroids. However, this recovers quickly
burning, irritation, ulceration. Systemic adverse effects — these occur rarely, are much less likely to occur than with oral corticosteroids, and are associated with high doses or prolonged treatment. The risk is higher with drops compared with sprays, as they are administered incorrectly more frequently. Systemic adverse effects include: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Decreased bone mineral density (...) Corticosteroids - topical (skin), nose, and eyes: Scenario: Intranasal corticosteroid treatment Scenario: Intranasal corticosteroid treatment | Management | Corticosteroids - topical (skin), nose, and eyes | CKS | NICE Search CKS… Menu Scenario: Intranasal corticosteroid treatment Corticosteroids - topical (skin), nose, and eyes: Scenario: Intranasal corticosteroid treatment Last revised in June 2020 Scenario: Intranasal corticosteroid treatment From birth onwards. What should I consider when
characteristics state that there is inadequate data to determine the safety of corticosteroid eye preparations in pregnancy [ ; ]. With systemic use of corticosteroids at higher doses, intrauterine growth inhibition and inhibition of the function of the adrenalcortex have been reported, but these effects have not been reported for ocular use [ ]. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intrauterine growth (...) with high doses prescribed for prolonged periods. Systemic adverse effects include: Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on in the CKS topic on . Cushing's syndrome. Visual disturbance, central serous chorioretinopathy, cataract, glaucoma. If a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation. For more information on the systematic adverse effects of corticosteroids
Corticosteroids - topical (skin), nose, and eyes Corticosteroids - topical (skin), nose, and eyes | Topics A to Z | CKS | NICE Search CKS… Menu Corticosteroids - topical (skin), nose, and eyes Corticosteroids - topical (skin), nose, and eyes Last revised in June 2020 Corticosteroids are synthetic analogues of the natural hormones that are produced by the adrenalcortex. Management Background information Corticosteroids - topical (skin), nose, and eyes: Summary Corticosteroids are synthetic (...) analogues of the natural hormones that are produced by the adrenalcortex. Local corticosteroids are predominantly glucocorticoids. They have four main effects: Anti-inflammatory. Immunosuppressive. Anti-proliferative (anti-mitotic). Vasoconstrictive. Topicalcorticosteroids exert these effects on the skin: Eczema — the anti-inflammatory and immunosuppressive effects are important. Psoriasis — is characterized by rapid cell turnover, and the anti-mitotic effects are important. Intranasal corticosteroids
. Applicability The evidence, while of low quality, still supports the application of topicalcorticosteroids to reduce the healing time of aphthous ulcers. The studies also report a reduction in the occurrence of new ulcers, the size of the ulcers, and the pain experienced by the patient due to the ulcers. A study evaluated in the systematic review shows that topicalcorticosteroids used intraorally do not cause adrenal suppression, if the patient uses them as instructed. Specialty/Discipline (Oral Medicine (...) TopicalCorticosteroids Improve Healing Time in Patients with Aphthous Ulcers UTCAT3273, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title TopicalCorticosteroids Improve Healing Time in Patients with Aphthous Ulcers Clinical Question In patients with aphthous ulcers, does treatment with topicalcorticosteroids, as compared to a placebo, improve healing time of the ulcers? Clinical Bottom Line Patients treated
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topicalcorticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab (...) substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topicalcorticosteroids versus placebo with topicalcorticosteroids in adults with moderate-to-severe atopic dermatitis.In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS
2017LancetControlled trial quality: predicted high
Psoriasis patientsâ€™ experiences concerning medical adherence to treatment with topicalcorticosteroids Nonadherence to topical treatment of psoriasis is a common cause of treatment failure. This focus group study was conducted to obtain the patients' own experiences and explanations regarding medical adherence. The participants consisted of eight primary adherent patients with moderate psoriasis treated with corticosteroid or corticosteroid-calcipotriol combinations, purposefully sampled (...) in the prescriber, diverging information from health care personnel, experiencing side effects, having fear of side effects, impractical formulations of topical products, and impatience regarding time before an effect of the treatment was observed. From this study, the recommendations for the prescribing doctor to improve medical adherence are, the doctor needs to take time to listen to the patient, prescribe a topical product that is easy to apply and less greasy, inform the patients about benefits from
Safety of topicalcorticosteroids in pregnancy. Topicalcorticosteroids are the most frequently prescribed dermatological treatment and are frequently used by pregnant women with skin conditions. However, little is known about their safety in pregnancy.To assess the effects of topicalcorticosteroids on pregnancy outcomes.On 5th May 2009 we searched the Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, CENTRAL (The Cochrane Library 2009 (...) , Issue 2), MEDLINE (from 2003), and EMBASE (from 2005). We searched LILACS, CINAHL, British Nursing Index, SCI-EXPANDED, BIOSIS Previews, Conference Papers Index, and Conference Proceedings Citation Index-Science from inception to May 2009. We scanned the bibliographies of the included studies, published reviews, and articles that had cited the included studies. Pharmaceutical companies that have introduced an original topicalcorticosteroid product were contacted.Randomised controlled trials
Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. To determine the clinical effectiveness of topical intranasal corticosteroids in children with bilateral otitis media with effusion.Double blind randomised placebo controlled trial.76 Medical Research Council General Practice Research Framework practices throughout the United Kingdom, between 2004 and 2007.217 (...) ) at one month (primary end point), three months, and nine months; adverse events; three month diary symptoms. Results 41% (39/96) of the topical steroid group and 45% (44/98) of the placebo group were cured in one or both ears at one month (difference favouring placebo 4.3% (95% confidence interval -9.3% to 18.1%). Poisson regression was done with adjustment for four pre-specified covariates (clinical severity, P=0.003; atopy, P=0.67; age, P=0.92; season, P=0.71). The adjusted relative risk at one
A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Topicalcorticosteroids as adjunctive therapy for bacterial keratitis. Bacterial keratitis is a serious ocular infectious disease that can lead to severe visual disability. Risk factors for bacterial corneal infection include contact lens wear, ocular surface disease, corneal trauma and previous ocular or eyelid surgery. Topical antibiotics constitute the mainstay of treatment in cases of bacterial keratitis where as the use of topicalcorticosteroids remains controversial. Topical (...) , an online database of ongoing trials (www.clinicaltrials.gov), reference lists of included trials, earlier reviews and the American Academy of Ophthalmology guidelines. We also contacted experts to identify any unpublished and ongoing randomized trials.We included randomized controlled trials evaluating adjunctive therapy with topicalcorticosteroids in people with bacterial keratitis.Two review authors independently screened all the retrieved articles. Methodological quality of the one included trial
A cost-utility analysis of pimecrolimus vs. topicalcorticosteroids and emollients for the treatment of mild and moderate atopic eczema A cost-utility analysis of pimecrolimus vs. topicalcorticosteroids and emollients for the treatment of mild and moderate atopic eczema A cost-utility analysis of pimecrolimus vs. topicalcorticosteroids and emollients for the treatment of mild and moderate atopic eczema Pitt M, Garside R, Stein K Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of topicalcorticosteroids (TCS) as a first-line treatment followed by pimecrolimus as a second-line treatment, and pimecrolimus as a first-line treatment followed by TCS, in the treatment of mild and moderate atopic eczema. Type
Frequency of application of topicalcorticosteroids for atopic eczema (TA81) Overview | Frequency of application of topicalcorticosteroids for atopic eczema | Guidance | NICE Frequency of application of topicalcorticosteroids for atopic eczema Technology appraisal guidance [TA81] Published date: 25 August 2004 Share Guidance on using topicalcorticosteroids for people with atopic eczema. Guidance development process Is this guidance up to date? . We found nothing new that affects